Clinical and Translational Radiation Oncology最新文献

{"title":"Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival","authors":"Robert Rulach ,&nbsp;Stephen Harrow ,&nbsp;Anthony J. Chalmers ,&nbsp;John Fenwick","doi":"10.1016/j.ctro.2025.101036","DOIUrl":"10.1016/j.ctro.2025.101036","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Loco-regional recurrence is seen in up to 50 % of patients with non-small cell lung cancer (NSCLC) by 2 years after curative intent radiotherapy (RT). For these patients, radical re-irradiation (re-RT) is possible, but data is lacking regarding efficacy and radiation dose response, especially about conventionally fractionated re-irradiation. We analysed associations between survival following re-irradiation and RT dose, to guide clinicians regarding target re-RT dose, and predict re-treatment efficacy.</div></div><div><h3>Material and methods</h3><div>We performed a literature search for studies primarily comprised of NSCLC patients that detailed 2-year overall survival (OS_2-yr) rates and delivered doses. These data were collated with intervals between treatments, PTV sizes and use of concurrent chemotherapy where this information was available. Logistic regression analyses of associations between OS_2-yr and treatment and patient factors were carried out. Doses required for 30% and 50% OS_2-yr were calculated.</div></div><div><h3>Results</h3><div>We identified 20 suitable studies (675 patients). In univariable models, OS_2-yr was significantly associated with the initial RT dose, re-RT dose and chemotherapy use but not the interval. The best multivariable OS_2-yr model according to the Akaike Information Criterion included only the re-RT dose (p &lt; 0.05) and described the data well (Hosmer-Lemeshow p-value = 0.385). This model predicted OS_2-yr rates of 30 % and 50 % at re-RT equivalent doses in 2 Gy fractions (EQD2s) of 49.8 Gy₁₀ (95 % CI 36.4, 58.0 Gy₁₀) and 76.5 Gy₁₀ (95 % CI 70.8, 82.7 Gy₁₀) respectively.</div></div><div><h3>Conclusion</h3><div>OS_2-yr following re-RT of recurrent NSCLC is significantly associated with retreatment dose. A reasonable target dose for re-RT is EQD2s &gt; 50 Gy₁₀ with survival rates continuing to increase to 85 Gy₁₀.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101036"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144892913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reirradiation clinical practice in gastrointestinal abdominal malignancies: an international reirradiation collaborative group (ReCOG) systematic review","authors":"Nauman H. Malik ,&nbsp;John P. Plastaras ,&nbsp;Stefanie Corradini ,&nbsp;Laura A. Dawson ,&nbsp;Maria A. Hawkins ,&nbsp;Kilian E. Salerno ,&nbsp;Charles S. Mayo ,&nbsp;Emma M. Dunne ,&nbsp;Dorota Gabryś ,&nbsp;Clemens Grassberger ,&nbsp;Theodore S. Lawrence ,&nbsp;Manju Sharma ,&nbsp;Alanah M. Bergman ,&nbsp;Dawn Owen ,&nbsp;Ali Zaila ,&nbsp;Soumon Rudra ,&nbsp;Michael Velec ,&nbsp;Donna H. Murrell","doi":"10.1016/j.ctro.2025.101033","DOIUrl":"10.1016/j.ctro.2025.101033","url":null,"abstract":"<div><h3>Purpose</h3><div>Reirradiation in abdominal malignancies has grown more common with advanced radiotherapy techniques. However, clinical use and implementation varies, and there remains limited consensus on best practices for reirradiation. In this systematic review, a multidisciplinary team treating gastrointestinal and hepatobiliary malignancies within the Reirradiation Collaborative Group (ReCOG) convened to review published literature on reirradiation in the abdomen to offer insights into patient selection, radiotherapy planning, risk management, and assessing knowledge gaps for future development of guidelines.</div></div><div><h3>Methods and Materials</h3><div>A systematic search of Cochrane Central, CINAHL Plus, EMBASE, and PubMed up to August 30, 2024, was conducted as per Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) framework. Data on patient characteristics, radiation doses, dose constraints, treatment outcomes, and toxicities were extracted. Where feasible, pooled weighted analyses were performed.</div></div><div><h3>Results</h3><div>Thirty-three studies involving 1,264 patients met inclusion criteria: 30 were retrospective and 3 prospective. The median number of patients reported per study was 26 (range 2–245). Of the reported tumor sites, 718 patients had liver tumors and 277 pancreas, with smaller numbers of mixed/lymph node targets. Reirradiation doses, fractionation schemes, and dose constraints varied widely; only half of the studies provided explicit organ-at-risk constraints. Three studies included patients treated with palliative intent. Median overall survival ranged from 5.9 to 44 months, with a pooled weighted median OS of 19.6 months across 20 studies that reported it. One-year local control rates ranged from 19 % to 93 %, with severe (grade ≥ 3) toxicities typically reported in 5–15 % of patients, although one study reported 25 % lethal RILD in liver reirradiation.</div></div><div><h3>Conclusion</h3><div>Reirradiation in abdominal malignancies appears to be able to achieve meaningful local control and survival in select patients, though heterogeneity in planning, dosing, and toxicity reporting remains a major challenge for establishing best practices. Standardized reporting of doses, constraints, and dose-volume relationships are needed to guide safe and effective reirradiation in this setting.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101033"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144852277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer","authors":"Dayu Xu ,&nbsp;Yechun Pang ,&nbsp;Jinghan Qu ,&nbsp;Jiuang Mao ,&nbsp;Tiantian Guo ,&nbsp;Shanshan Jiang ,&nbsp;Yue Zhou ,&nbsp;Li Chu ,&nbsp;Xi Yang ,&nbsp;Xiao Chu ,&nbsp;Shengping Wang ,&nbsp;Tong Tong ,&nbsp;Zhengfei Zhu ,&nbsp;Jianjiao Ni","doi":"10.1016/j.ctro.2025.101038","DOIUrl":"10.1016/j.ctro.2025.101038","url":null,"abstract":"<div><h3>Background</h3><div>Hypofractionated stereotactic radiotherapy (fSRT) is increasingly used for brain metastases (BMs) from non-small cell lung cancer (NSCLC). However, relevant data concerning treatment outcomes of fSRT and clinical utility of re-irradiation using fSRT (re-fSRT) remain scarce.</div></div><div><h3>Methods</h3><div>Consecutive NSCLC patients with fSRT-treated BMs from May 2018 to May 2022 were included. The cumulative incidence of intracranial local recurrence (iLR), intracranial progressive disease (iPD) and symptomatic radiation necrosis (sRN) were calculated from the initiation of fSRT, choosing death as the competing event. Patients with limited iPD (number ≤5 and size ≤3 cm) and without iLR developed within 12 months, were classified as re-fSRT candidates. The clinical value of re-fSRT and dosimetric predictors of sRN were investigated.</div></div><div><h3>Results</h3><div>With a median follow-up of 22.3 months, the 1-year, 2-year and 3-year cumulative incidence of iLR among the 218 identified patients were 8.1 %, 12.3 %, 17.8 %, respectively. Biological effective dose, total tumor volume and concurrent systemic therapy were associated with the risk of iLR. Notably, 45 (76.3 %) of the 59 patients with iPD were feasible for re-fSRT. Re-fSRT was performed in 19 (42.2 %) of the 45 candidates and associated with improved survival (<em>p</em> = 0.010). The 1-year, 2-year and 3-year cumulative incidence of sRN in the whole population were 4.5 %, 10.3 %, 17.7 %, respectively. Moreover, sRN occurred in 3 (15.8 %) patients receiving re-fSRT and Brain V20Gy was found to be associated with the risk of sRN.</div></div><div><h3>Conclusion</h3><div>fSRT is a promising treatment for limited BMs from NSCLC and some patients may benefit from re-fSRT.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101038"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144902886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient experience and shared decision-making in HPV-positive oropharyngeal cancer: A systematic review of qualitative and quantitative evidence","authors":"Pierluigi Bonomo ,&nbsp;Katherine J. Taylor ,&nbsp;Maria Chiara Bassi ,&nbsp;Valentina Bressan ,&nbsp;Luca Ghirotto","doi":"10.1016/j.ctro.2025.101028","DOIUrl":"10.1016/j.ctro.2025.101028","url":null,"abstract":"<div><h3>Introduction</h3><div>Human papillomavirus (HPV)-related oropharyngeal cancer generally has a good prognosis and can be successfully treated with different modalities (including de-escalation); therefore, shared decision-making regarding treatment has a special role. We aimed to assess how the patients experience this diagnosis in light of optimizing shared decision-making.</div></div><div><h3>Materials and Methods</h3><div>MEDLINE, Embase, CINAHL, PsycINFO, and Scopus were searched in two systematic reviews (CRD42023484134 and CRD42024501211). Studies were included if they described how patients with HPV-positive oropharyngeal cancer experience their illness and what factors they consider when confronted with a treatment decision. A results-based convergent synthesis design was adopted to analyze qualitative and quantitative evidence separately, then integrated through a narrative synthesis approach.</div></div><div><h3>Results</h3><div>Nine of the 1978 articles met the selection criteria, resulting in a total of 392 patients being included. Five factors influencing patient decision-making were identified from the quantitative evidence: priority for cure and survival, and preference for de-intensification, which resulted in top-ranked issues for over 65% and 73% of patients who expressed them, respectively. Three qualitative themes were identified to encapsulate patient experiences, encompassing domains related to receiving and dealing with the diagnosis, decision-making, and perception of the impact of treatments. Based on these findings, a prompting list was created as a suggested communication toolkit for clinical practice.</div></div><div><h3>Conclusions</h3><div>Our systematic review of the literature highlighted the multifaceted and complex experiences of patients facing the diagnosis of a curatively treatable HPV-positive oropharyngeal cancer. Our findings should be considered for optimal shared decision-making in clinical practice.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101028"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144809751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous β− particle exposure: A study of DNA damage in ex vivo peripheral blood mononuclear cells irradiation with Radioiodine","authors":"Laura Mazzitelli-Fuentes ,&nbsp;Lara Negrin ,&nbsp;Virginia Venier ,&nbsp;Humberto Romano ,&nbsp;Lucia Pereira ,&nbsp;Jerónimo Leberle ,&nbsp;Maria Soledad Ausas ,&nbsp;Ananya Choudhury ,&nbsp;Luisa V. Biolatti","doi":"10.1016/j.ctro.2025.101040","DOIUrl":"10.1016/j.ctro.2025.101040","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Targeted radionuclide therapy (TRT) is a promising cancer treatment, but insufficient knowledge of the biological dose–response relationships limits its efficacy. The aim of this study was to characterize DNA damage in peripheral blood mononuclear cells (PBMCs) exposed to β-continuous irradiation (¹³¹I), and to assess its relationship with the absorbed dose, using two biomarkers: dicentric chromosomes and γ-H2AX foci.</div></div><div><h3>Materials and methods</h3><div>PBMCs from healthy donors were exposed to ¹³¹I at various activities (0.37–3.7 MBq) and times (1, 4, 24 h). Absorbed doses were calculated using the Medical Internal Radiation Dose formalism. DNA damage was assessed by chromosomal aberration frequency and γ-H2AX foci quantification. Lithium chloride (LiCl) was used to evaluate the rescue of delayed foci formation after 24 h exposure.</div></div><div><h3>Results</h3><div>Continuous β-irradiation induced a linear increase in CAs (α = 0.0643 ± 0.0068), in contrast to the linear-quadratic response observed in acute X-ray exposure (α = 0.0359 ± 0.0093, β = 0.0673 ± 0.0042). The frequency of CAs is lower under radionuclide irradiation compared to X-rays. γ-H2AX increased significantly at 1 and 4 h of continuous exposure but diminished at 24 h, despite continuous irradiation. LiCl treatment partially restored γ-H2AX foci levels at 24 h.</div></div><div><h3>Conclusion</h3><div>Dose-response relationship under continuous β-irradiation, assessed by CAs, follows a linear trend. DNA damage induced foci show a time-dependent dynamic. The decline in foci at 24 h, reversible with LiCl, highlights the limitations of γ-H2AX as a biomarker under prolonged irradiation conditions. These findings emphasize the need for optimized dosimetry methods and identify reliable biomarkers in TRT.</div><div>Abbreviations: TRT, targeted radionuclide therapy; MIRD, Medical Internal Radiation Dose; EBRT, external beam radiotherapy; LQ, linear-quadratic; DCA, dicentric chromosome assay; DSB, double strand break; PBMCs, peripheral blood mononuclear cells; PB, peripheral blood; FBS, fetal bovine serum; PBS, phosphate-buffered saline; CAs, chromosomal aberrations; RT, room temperature.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101040"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Reply to Topkan et al.","authors":"Shengjin Dou ,&nbsp;Guopei Zhu","doi":"10.1016/j.ctro.2025.100990","DOIUrl":"10.1016/j.ctro.2025.100990","url":null,"abstract":"<div><div>We appreciate the insightful letter from Topkan et al., which highlights important considerations regarding postoperative concurrent chemoradiotherapy (CCRT) in highrisk head and neck adenoid cystic carcinoma (ACC) and offers valuable perspectives on future directions. First of all, we agree that the standard use of CCRT cannot be recommended until prospective evidence is available. While chemotherapy may offer some benefit in local control and overall survival in ACC patients, it inevitably increases the risk of treatment-related toxicities. Therefore, the routine use of CCRT in ACC patients cannot be recommended unless sufficient survival benefit is demonstrated in prospective trials. Second, we recognize that one of the limitations of the study was the relatively small sample size, which may have limited its ability to detect statistically significant differences between the CCRT and RT-alone groups. Given the low incidence of ACC, recruiting an adequately large cohort across multiple centers would require substantial collaboration and coordination. This presents a significant challenge, as the rarity of ACC often results in slow patient recruitment, potentially affecting the generalizability of the findings. Nevertheless, with robust multi-institutional collaboration, such studies remain feasible and could yield valuable insights into treatment outcomes for this patient population.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 100990"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in use of magnetic resonance imaging and partial breast irradiation between 2011–2022 in the Netherlands: A population-based study","authors":"Y.A. Civil ,&nbsp;A.H. Eijkelboom ,&nbsp;A.E. Veldink ,&nbsp;M.C. van Maarenc ,&nbsp;J.H. Maduro ,&nbsp;K.M. Duvivier ,&nbsp;S. Siesling ,&nbsp;H.J.G.D. van den Bongard","doi":"10.1016/j.ctro.2025.101039","DOIUrl":"10.1016/j.ctro.2025.101039","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to investigate whether the introduction of partial breast irradiation (PBI) was associated with increased MRI use in the Netherlands from 2011 to 2022, and examined the impact of MRI on treatment and outcomes.</div></div><div><h3>Methods</h3><div>Women aged ≥50 who underwent surgery (without preoperative systemic therapy) for cT1-2N0M0 breast cancer or DCIS between 2011 and 2022 were selected from the Netherlands Cancer Registry. Logistic regression was used to analyze associations between MRI and treatment or surgical radicality, stratified by tumour type. Subgroup analyses were performed in patients meeting ASTRO PBI criteria (unifocal cT1, grade 1/2, ER-positive, pure DCIS ≤ 2,5 cm).</div></div><div><h3>Results</h3><div>Among 119,768 patients, 35,863 (30 %) received MRI, increasing from 24 % (2011) to 37 % (2022). PBI use increased from 3 % (2017) to 21 % (2022). MRI was not associated with the probability of receiving PBI (OR 0.98, 95 % CI:0.90–1.07). In patients with invasive breast cancer, MRI was associated with fewer DCIS-involved margins (OR 0.81, 95 % CI:0.74–0.89), but a higher probability of mastectomy (OR 1.29, 95 % CI:1.24–1.34). In patients with an ASTRO-defined PBI indication, MRI use was associated with a decreased likelihood of receiving PBI in invasive cancer (OR:0.66, 95 % CI:0.60–0.72) and DCIS (OR:0.80, 95 % CI:0.75–0.85).</div></div><div><h3>Conclusion</h3><div>This study shows rising trends in PBI and MRI use in the Netherlands from 2011 to 2022. MRI reduced PBI eligibility and enhanced surgical precision by less involved margins in patients with cT1N0 breast cancer without PST.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101039"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant prostate artery embolization prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation","authors":"Vaseem M. Khatri ,&nbsp;G.Daniel Grass ,&nbsp;Ram Thapa ,&nbsp;Laura Maun-Garcia ,&nbsp;Kujtim Latifi ,&nbsp;Arash O. Naghavi ,&nbsp;Aditya Garg ,&nbsp;Daniel Fernandez ,&nbsp;Javier Torres-Roca ,&nbsp;Anupam Rishi ,&nbsp;Omeed Jazayeri-Moghaddas ,&nbsp;Julio Pow-Sang ,&nbsp;Peter A.S. Johnstone ,&nbsp;Kosj Yamoah ,&nbsp;Nainesh Parikh","doi":"10.1016/j.ctro.2025.101035","DOIUrl":"10.1016/j.ctro.2025.101035","url":null,"abstract":"<div><h3>Background</h3><div>Radiation therapy (RT) for prostate cancer has gastrointestinal and genitourinary toxicities, greater with baseline lower urinary tract symptoms (LUTS) and larger prostate volume (PV). Prostate artery embolization (PAE) improves LUTS and PV before RT. This study evaluates the durability of LUTS improvement from neoadjuvant PAE before prostate RT and oncologic outcomes.</div></div><div><h3>Methods</h3><div>We retrospectively identified patients receiving definitive prostate RT following PAE from a prospective database, including International Prostate Symptom Scores (IPSS), pre- and post-PAE MRI PV, and toxicity per CTCAEv5.0. Primary objective was LUTS by IPSS. Secondary objectives included biochemical recurrence-free survival (bRFS), local recurrence, and distant metastasis.</div></div><div><h3>Results</h3><div>From 9/2017–5/2024, 82 patients underwent PAE before RT, with 30.5 % having unfavorable intermediate risk. RT consisted of conventional fractionation (n = 21), moderate hypofractionation (n = 42), SBRT (n = 11), and EBRT/brachytherapy boost (n = 8); a subset of patients received androgen deprivation therapy. Pelvic lymph nodes were treated in 28 (34 %) patients. Median pre-PAE IPSS was 18 (range 2–34), PV 90 cc (14.2–240), and PSA 8.4 ng/mL (0.02–125.5). Post-PAE, mean IPSS reduction was 10.7 points (−13–30). Mean PV reduction was 30.9 cc (−9–136) or 32 %. PAE converted 52 % of patients contraindicated by size/IPSS for brachytherapy/SBRT. Post-RT, mean IPSS changes at 3, 6, 12, 18 and 24 months were −8.7, −8.5, −9.5, −8.9, and −7.6, respectively (<em>p</em> &lt; 0.001). At 24.2-month median follow-up, 1 local recurrence occurred. Two-year bRFS was 92 % for non-metastatic patients.</div></div><div><h3>Conclusion</h3><div>Urinary improvement is durable after RT in men with large prostates and/or high LUTS burden with neoadjuvant PAE, and no increased risk of recurrence at intermediate-term follow-up. Further investigation is warranted.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101035"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144866096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer”","authors":"Parth Aphale,&nbsp;Himanshu Shekhar,&nbsp;Shashank Dokania","doi":"10.1016/j.ctro.2025.101031","DOIUrl":"10.1016/j.ctro.2025.101031","url":null,"abstract":"<div><div>The recently published study by Zang et al. offers valuable insight into PSMA-PET/CTbased response assessment in patients with oligometastatic prostate cancer (PCa) undergoing stereotactic ablative body radiotherapy (SABR), demonstrating an impressive 5-year local control rate of 86 % and progressive reduction in SUVmax values across follow-up intervals [<span><span>1</span></span>]. While the findings reinforce the utility of PSMAPET/CT as a potential biomarker for local tumor control, certain methodological and interpretive issues merit deeper consideration.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101031"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144826473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining failure patterns and dynamics in locally advanced pharyngeal and laryngeal SCC following radiotherapy: Real-World Insights in the modern Era!","authors":"Linda Agolli ,&nbsp;Luise Reinhard ,&nbsp;Christine Langer ,&nbsp;Christoph Arens ,&nbsp;Gabriele A. Krombach ,&nbsp;Sebastian Harth ,&nbsp;Andreas Lurtz ,&nbsp;Ann-Katrin Exeli ,&nbsp;Stefan Gattenlöhner ,&nbsp;Daniel Habermehl","doi":"10.1016/j.ctro.2025.101026","DOIUrl":"10.1016/j.ctro.2025.101026","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to evaluate the prevalence and patterns of locoregional recurrence (LRR), outcome and prognostic factors in patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, and larynx treated with intensity-modulated or volume-modulated arc therapy definitive radiotherapy (RT) with or without systemic therapy.</div></div><div><h3>Methods</h3><div>Of the 213 reviewed patients treated between 2016 and 2023, 177 met the inclusion criteria. LRR was defined as recurrence in the primary tumor region or regional nodes. Failure patterns were classified based on a recurrence model, including central high-dose (A), peripheral high-dose (B), central elective(C), peripheral elective (D), and out-of-field recurrence (E).</div></div><div><h3>Results</h3><div>LRR was observed in 50/177 (28.2%) patients and 81 recurrent lesions. Most recurrences occurred within the first year after RT (39/177, 22.0%), predominantly in HPV-negative patients. The majority of failures were within the high-dose target volume (65% type A, 14% type C), with marginal recurrences (types B and D) occurring in 22% of cases and type E in 5% of patients. HPV-positive patients had fewer LRR (16.0% vs. 34.4% in HPV-negative patients).</div><div>Multivariate analysis identified HPV status as a significant prognostic factor for OS, PFS and LRR. The occurrence of distant metastases showed a negative impact on OS, PFS and LRR. LRR showed a trend toward worse OS (p = 0.072). Chemotherapy had a significant effect on PFS and LRR.</div></div><div><h3>Conclusion</h3><div>LRR remains a challenge, especially in HPV-negative patients. Most failures occurred centrally, but marginal and extra-field recurrences highlight the need for improved target delineation and adaptive RT strategies. Further research is needed to optimize treatment in high-risk patients.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"55 ","pages":"Article 101026"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}